Design Therapeutics (DSGN)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	15.09 mm	15.09 mm	15.09 mm	15.09 mm	15.09 mm	15.09 mm
Cash burn (monthly)	1.54 mm	1.27 mm	6.44 mm	6.50 mm	3.72 mm	4.35 mm
Cash used (since last report)	3.46 mm	2.86 mm	14.48 mm	14.62 mm	8.37 mm	9.79 mm
Cash remaining	11.63 mm	12.23 mm	612.23 k	472.05 k	6.72 mm	5.30 mm
Runway (months of cash)	7.6	9.6	0.1	0.1	1.8	1.2

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2024

DSGN institutional ownership history Ownership history

83.6% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	97	104	-6.7%
Opened positions	14	15	-6.7%
Closed positions	21	9	+133.3%
Increased positions	34	29	+17.2%
Reduced positions	22	34	-35.3%

13F shares	Current	Prev Q	Change
Total value	201.07 bn	167.38 bn	+20.1%
Total shares	47.62 mm	46.23 mm	+3.0%
Total puts	2.60 k	16.50 k	-84.2%
Total calls	4.60 k	2.30 k	+100.0%
Total put/call ratio	0.6	7.2	-92.1%

Largest owners	Shares	Value	Change
SR One Capital Fund I Aggregator	6.53 mm	$54.37 mm	0.0%
SR One Capital Management	6.53 mm	$40.27 bn	0.0%
Logos Global Management	4.22 mm	$26.02 bn	0.0%
Irrevocable Trust #1 dated April 22, 2019 Light	3.83 mm	$19.06 mm	0.0%
Irrevocable Trust #1 dated April 22, 2019 Star	3.83 mm	$19.06 mm	0.0%
BlackRock	2.58 mm	$15.92 bn	+9.4%
Frazier Life Sciences Management	1.95 mm	$12.05 bn	+3.2%
Point72 Asset Management	1.86 mm	$11.46 bn	+16.0%
Baker Bros. Advisors	1.74 mm	$10.76 bn	0.0%
Tang Capital Management	1.48 mm	$9.14 bn	0.0%

Largest transactions	Shares	Bought/sold	Change
Driehaus Capital Management	776.08 k	+776.08 k	NEW
MPM Oncology Impact Management	559.55 k	+559.55 k	NEW
Citadel Advisors	958.79 k	+383.24 k	+66.6%
EcoR1 Capital	426.68 k	+372.85 k	+692.6%
Prescott Group Capital Management, L.L.C.	0.00	-343.00 k	EXIT
Assenagon Asset Management	56.62 k	-289.58 k	-83.6%
Jacobs Levy Equity Management	18.26 k	-262.01 k	-93.5%
Point72 Asset Management	1.86 mm	+256.01 k	+16.0%
BlackRock	2.58 mm	+220.80 k	+9.4%
Millennium Management	0.00	-207.26 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

DSGN insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
9 Sep 25	Justin D. Gover	Stock option Common Stock	Grant	Acquire A	No	No	6.64	15,833	105.13 k	15,833
9 Sep 25	Justin D. Gover	Stock option Common Stock	Grant	Acquire A	No	No	6.64	30,000	199.20 k	30,000
13 Aug 25	Arsani William	Common Stock	Sell	Dispose S	Yes	No	5.25	217,627	1.14 mm	1,000,000
13 Aug 25	Arsani William	Common Stock	Sell	Dispose S	Yes	No	5.25	345,000	1.81 mm	2,655,000
10 Jun 25	Deepa Prasad	Stock Option Common Stock	Grant	Acquire A	No	No	4.01	19,000	76.19 k	19,000
10 Jun 25	Arsani William	Stock Option Common Stock	Grant	Acquire A	No	No	4.01	19,000	76.19 k	19,000

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Leerink Partners Upgrades Design Therapeutics to Outperform, Raises Price Target to $14

3 Dec 25

Leerink Partners analyst Joseph Schwartz upgrades Design Therapeutics (NASDAQ:DSGN) from Market Perform to Outperform and raises the price target from $7 to $14.

Nutex Health Posts Strong Q3 Results, Joins PACS Group, Walmart, Cerence And Other Big Stocks Moving Higher On Thursday

20 Nov 25

RBC Capital Upgrades Design Therapeutics to Outperform, Raises Price Target to $13

20 Nov 25

RBC Capital analyst Leonid Timashev upgrades Design Therapeutics (NASDAQ:DSGN) from Sector Perform to Outperform and raises the price target from $6 to $13.

RBC Capital Maintains Sector Perform on Design Therapeutics, Raises Price Target to $6

6 Nov 25

Design Therapeutics Q3 EPS $(0.30) Beats $(0.34) Estimate

5 Nov 25